DocGo Inc (DCGO)vsMerck & Company Inc (MRK)
DCGO
DocGo Inc
$0.71
-0.20%
HEALTHCARE · Cap: $70.92M
MRK
Merck & Company Inc
$109.18
-1.60%
HEALTHCARE · Cap: $274.03B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 20077% more annual revenue ($65.01B vs $322.20M). MRK leads profitability with a 28.1% profit margin vs -56.6%. MRK earns a higher WallStSmart Score of 59/100 (C).
DCGO
Hold36
out of 100
Grade: F
MRK
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for DCGO.
Margin of Safety
-13.2%
Fair Value
$96.48
Current Price
$109.18
$12.70 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Every $100 of equity generates 37 in profit
Strong operational efficiency at 32.8%
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Generating 1.8B in free cash flow
Areas to Watch
Grey zone — moderate risk
Smaller company, higher risk/reward
Weak financial health signals
ROE of -89.0% — below average capital efficiency
Weak financial health signals
Expensive relative to growth rate
Earnings declined 19.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : DCGO
The strongest argument for DCGO centers on Price/Book, Debt/Equity.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.
Bear Case : DCGO
The primary concerns for DCGO are Altman Z-Score, Market Cap, Piotroski F-Score.
Bear Case : MRK
The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
DCGO profiles as a turnaround stock while MRK is a value play — different risk/reward profiles.
DCGO carries more volatility with a beta of 0.98 — expect wider price swings.
MRK is growing revenue faster at 5.0% — sustainability is the question.
MRK generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (59/100 vs 36/100), backed by strong 28.1% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
DocGo Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
DocGo Inc. is a forward-thinking mobile healthcare service provider that transforms patient access through its cutting-edge logistics and telehealth platform. Focusing on urgent care, diagnostic testing, and health screenings, the company not only improves patient experiences but also optimizes healthcare delivery across various settings. With its robust technological advancements and dedication to expanding healthcare access, DocGo stands out as a compelling investment opportunity in the fast-growing healthtech landscape, appealing to institutional investors seeking growth potential.
Visit Website →Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other MEDICAL CARE FACILITIES Stocks
Want to dig deeper into these stocks?